Thalidomide in the management of multiple myeloma

Seminars in Oncology

Volumn 28, Issue 6, 2001, Pages 577-582

  Barlogie, B ^a   Tricot, G ^a   Anaissie, E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; HEMOGLOBIN; IMMUNOGLOBULIN M; PARAPROTEIN; THALIDOMIDE;

ADULT; AGED; ANGIOGENESIS; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

EID: 0035210668     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90027-2     Document Type: Article

References (18)

1. Thalidomide is an inhibitor of angiogenesis
2. Antitumor activity of thalidomicie in refractory multiple myeloma
3. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
4. Thalidomide in patients with advanced myeloma: Survival prognostic factors
5. Durable response to thalidomide in relapsed/refractory multiple myeloma (MM)
6. Achievement of maximal disease response to thalidomide is limited by patients' tolerance more often than disease resistance
7. Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma
8. Interferon-α2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM)
9. Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma
10. Thalidomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens
11. Thalidomide and congenital abnormalities
12. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
13. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
14. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
15. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
16. Thalidomide plus dexamethasone and thalidomide alone as first-line therapy for newly diagnosed myeloma
17. Thalidomide (Thal) and immumomodulatory derivates (IDS) augment natural killer (NK) cell cytotoxicity in multiple myeloma (MM)
18. Thalidomide in the management of multiple myeloma